{"id":813,"date":"2024-08-07T16:07:58","date_gmt":"2024-08-07T15:07:58","guid":{"rendered":"https:\/\/project.eortc.org\/e2-radiate\/?p=813"},"modified":"2024-08-08T15:19:43","modified_gmt":"2024-08-08T14:19:43","slug":"acute-toxicity-in-patients-with-oligometastatic-cancer","status":"publish","type":"post","link":"https:\/\/project.eortc.org\/e2-radiate\/2024\/08\/07\/acute-toxicity-in-patients-with-oligometastatic-cancer\/","title":{"rendered":"Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2<\/sup>-RADIatE OligoCare cohort"},"content":{"rendered":"

Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2<\/sup>-RADIatE OligoCare cohort<\/h1><\/div><\/div><\/div><\/div><\/div>

Aim<\/strong>
\nTo evaluate acute toxicity at 6\u202fmonths after stereotactic body radiotherapy (SBRT) in patients with oligometastatic cancer within the OligoCare cohort.<\/p>\n

Material and methods<\/strong>
\nOligoCare is a prospective, registry-based, single-arm, observational study that aims to report prospective real-world data of patients with oligometastases from solid cancer treated with SBRT (NCT03818503). Primary tumor included non-small cell lung cancer (NSCLC), breast cancer (BC), colorectal cancer (CRC), and prostate cancer (PC). This analysis addresses a secondary endpoint of the trial, acute toxicity within 6\u202fmonths after SBRT.<\/p>\n<\/div>

<\/div><\/div><\/div>
\"To<\/span><\/div>
<\/div><\/div><\/div>

Results<\/strong>
\nOut of 1,597registered patients, 1\u2032468 patients were evaluated for acute toxicity. Globally, 290 (20\u202f%) had NSCLC primary disease, 227 (16\u202f%) had BC, 293 (20\u202f%) had CRC, and 658 (45\u202f%) had PC. Concomitant systemic treatment was administered in 527 (35.9\u202f%) patients. According to the EORTC\/ESTRO oligometastatic disease (OMD) classification, 828 (56\u202f%) patients had de novo OMD, 464 (32\u202f%) repeat OMD, and 176 (12\u202f%) induced OMD. Acute grade\u202f\u2265\u202f3 SBRT related adverse events were reported in 8 (0.5\u202f%) patients, including 2 (0.1\u202f%) fatal AEs. In particular, 6 (0.4\u202f%) grade 3 events were: 1 empyema, 1 pneumonia, 1 radiation pneumonitis, 1 radiation skin injury, 1 decreased appetite, and 1 bone pain. Among those 2 occurred in NSCLC patients, 2 in BC patients, and 1 in CRC and PC patients each. The two (0.1\u202f%) grade 5 toxicity were represented by: pneumonitis and cerebral hemorrhage.<\/p>\n

Conclusion<\/strong>
\nOligoCare is the largest prospective registry cohort on oligometastatic disease. Acute toxicity within 6\u202fmonths was low, confirming the safety of SBRT in the treatment of oligometastases.<\/p>\n

https:\/\/doi.org\/10.1016\/j.radonc.2024.110466<\/a><\/p>\n<\/div>

<\/div><\/div><\/div>

Filippo Alongi, Luca Nicosia, Umberto Ricardi, Marta Scorsetti, Daniela Greto, Panagiotis Balermpas, Yolande Lievens, P\u00e8tra Braam, Barbara Alicja Jereczek-Fossa, Karin Stellamans, Ivica Ratosa, Inga-Malin Simek, Heike Peulen, Piet Dirix, Luc Verbeke, Sara Ramella, Hossein Hemmatazad, Kaouthar Khanfir, Xavier Geets, Paul Jeene, Thomas Zilli, Beatrice Fournier, Catherine Fortpied, Felix Boakye Oppong, Piet Ost, Matthias Guckenberger<\/p>\n<\/div>

<\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":14,"featured_media":814,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-813","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publications"],"_links":{"self":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts\/813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/comments?post=813"}],"version-history":[{"count":5,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts\/813\/revisions"}],"predecessor-version":[{"id":816,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts\/813\/revisions\/816"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/media\/814"}],"wp:attachment":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/media?parent=813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/categories?post=813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/tags?post=813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}